Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-242 (Resatorvid) in septic shock: randomized, double-blind, placebo-controlled phase 3 trial
2007-005687-27Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in septic shock and respiratory failure comparing TAK-242 arm with Placebo arm (2 arms). Primary endpoint: 28-day all-cause mortality. Started Apr 2008; status: completed.
02
Drugs
resatorvid
03
Conditions
septic shockrespiratory failure
Beyond the preview
Go deeper on 2007-005687-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005687-27.